CMS Reinstates NovoCure's Billing Privileges Retroactively, Reversing Prior Revocation

summarizeSummary

NovoCure announced that CMS has rescinded the prior revocation of its U.S. subsidiary's billing privileges, reinstating them retroactively to December 17, 2025, and mitigating a significant operational risk.

check_boxKey Events

• CMS Billing Privileges Reinstated

  The Centers for Medicare & Medicaid Services (CMS) rescinded the revocation of Novocure Inc.'s billing privileges, reinstating them retroactively to December 17, 2025.

• Reversal of Prior Revocation

  This action reverses the previous revocation, which was disclosed on February 5, 2026, and was attributed to an administrative re-validation issue, not a substantive failure.

• No Expected Revenue Impact

  The company continued to provide services during the period of ineligibility and believes there will be no ultimate impact on its ability to recognize revenue for these services.

auto_awesomeAnalysis

This filing reports a critical positive development for NovoCure, as the Centers for Medicare & Medicaid Services (CMS) has rescinded the prior revocation of its U.S. subsidiary's billing privileges. The reinstatement, effective retroactively to December 17, 2025, directly reverses the significant negative news disclosed on February 5, 2026. This action removes a major operational and financial overhang, ensuring the company can continue to bill for its services to Medicare patients without interruption and expects no impact on revenue recognition. This is a substantial de-risking event for the company.